Hypereosinophilic Syndrome

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

Natural History of Hypereosinophilia and Hypereosinophilic Syndromes

Identification of New Markers in the Hypereosinophilic Syndrome

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic

Steroid Treatment for Hypereosinophilic Syndrome

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622

Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

Eosinophilia Diagnosis

Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome